Entwodiksyon: Gen yon lyen endispansab nan rechèch medikal, se sa ki, eksperyans bèt. Dapre estatistik enkonplè, dè milyon de bèt nan tout mond lan tonbe viktim eksperyans syantifik chak ane. Malgre ke li son san, li se tou yon pwosesis ke devlopman medikal dwe ale nan. Sepandan, ak devlopman nan teknoloji 3D bioprinting nan dènye ane yo, gen kèk konstriksyon bioprinted yo espere reyalize ranplasman fonksyonèl nan tisi k ap viv, epi piti piti reyalize objektif pou ranplase eksperyans bèt.
△In 2014, about 400,000 mice died in the laboratory
18 fevriye 2022 Yon pwojè Inyon Ewopeyen (EU)-finanse ap chèche diminye tès bèt nan rechèch medikal eksperimantal atravè bioprinting 3D. Kowòdone pa Institute of Bioengineering of Catalonia (IBEC), pwojè BRIGHTER (Bioprinting by Photolithography: Complex Tissue Engineering at High Rezolisyon ak vitès) ap devlope nouvo apwòch nouvo pou jeni tisi ak medikaman rejeneratif pwosesis bioprinting 3D pou diminye itilizasyon taksidèmi nan zòn sa yo. An patikilye, pwojè a konsantre sou fabwikasyon po moun lè l sèvi avèk yon teknik bioprinting roman ki baze sou fèy limyè lazè modele.
Professor Elena Martinez, coordinator of the BRIGHTER project, said: "Our innovative 3D bioprinting system not only achieves tissue closer to the real thing, but is also much faster than current systems, an essential factor in ensuring the viability of new tissue."
△ A small square containing a matrix of skin cells. Photo via IBEC.
Diminye tès bèt ak enprime 3D
Teknoloji bioprinting 3D te avanse nan gwo pwogrè pandan dis dènye dekad la, ak gwo pwogrè nan devlope tisi espesifik pasyan ki solid-. Pandan ke devlopman sa yo kenbe pwomès pou esè efikasite nan lavni, tisi yo toujou lajman eksperimantal, ak esè dwòg imen yo se dè dekad lwen. Sepandan, tou de akademi ak endistri yo ap travay pou chanje sa, ak Swedwa bioprinter maker CELLINK pwomèt pou avanse rechèch li yo nan modèl tès selil bèt inofansif ak lè l sèvi avèk modèl po miniature nan University of Stuttgart pou teste efikasite nan dwòg kansè nan yon lide pou elimine. tès bèt.
Elsewhere, Fluicell's Biopixlar platform has produced highly complex neural models that show potential for future clinical drug screening applications, while UpNano's NanoOne Bio system is focusing on the fabrication of cell culture microstructures that may have Helps reduce the number of animal experiments behind clinical trials.
△CELLINK has acquired in vitro technology specialist MatTek to create a harmless drug testing model. Photo via MatTek.
Yon altènativ ki pi imen nan tès bèt
In addition to IBEC, the Goethe University Frankfurt, the Technion Center in Israel and the biotechnology companies Mycronic and Cellendes are also participating in the BRIGHTER project. The program hopes to overcome many of the technical barriers that currently limit the fabrication of complex human tissue. The partners are collaborating on the development of a novel light-sheet bioprinting process capable of producing complex and accurate in vitro models that can be used for cosmetic and drug testing in the pharmaceutical industry and research settings. To fine-tune the technology, the BRIGHTER team is working to 3D print human skin, a highly complex tissue composed of multiple cell types and structures, such as sweat glands and hair follicles. Hydrogels will form a key component of the bioprinting process, as they form the basis for cells to grow and form new tissues, and they can also be personalized using a patient's own cells. To print skin with the desired structure, shape, and consistency, the researchers are using advanced imaging techniques that combine illumination from light sheets and high-resolution digital masks. By applying the laser directly to the hydrogel, the cells within it can be "patterned" and shaped into the right shape, allowing the team to control the stiffness, shape and size of the 3D printed structures.
The ability to shape hydrogels at a high level is especially critical for successfully printing human skin, because this tissue is made up of many layers of cells of different types. According to the BRIGHTER team, their bioprinting process was also able to create the blood vessels of the printed tissue and enable the function of sebaceous and sweat glands, as well as hair follicles to grow hair. Dr Nuria Torras, a postdoctoral researcher at IBEC, said: "We hope to be able to print a skin sample with an area of 1 square centimeter and a thickness of 1 mm in about 10 minutes with a cell viability rate of over 95 percent , greatly improving current bioprinting conditions. "The BRIGHTER project hopes that successful printing of the in vitro skin model will validate its potential for use in pharmaceutical and research settings, and ultimately reduce animal testing for drug and cosmetic testing.
Guangmai Teknoloji se pwofondman angaje nan sous limyè sante ak entelijan, bay yon seri konplè nan UVA UVB UVC dirije, enfrawouj IR dirije pwodwi VCSEL ak solisyon nan mache a. Li gen plizyè santèn patnè kalite siperyè nan mache domestik ak etranje pou ankouraje itilizasyon teknoloji limyè pou kreye yon lavi ki an sante ak entelijan. .
